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Summary
Methionine synthase (MS) catalyses the methylation of
homocysteine to methionine and requires the vitaminB12
derivative, methylcobalamin, as cofactor. We and others
have recently cloned cDNAs for MS and described mu-
tations associated with the cblG complementation group
that correspond to MS deficiency. A subset of cblG,
known as “cblG variant,” shows no detectable MS ac-
tivity and failure of [57Co]CN cobalamin to incorporate
into MS in patient fibroblasts. We report the mutations
responsible for three cblG-variant patients, two of them
siblings, who presented with neonatal seizures, severe
developmental delay, and elevated plasma homocysteine.
Cell lines from all three patients were negative by north-
ern blotting, though trace MS mRNA could be detected
by means of phosphorimage analysis. Reverse transcrip-
tase–PCR, SSCP, and nucleotide sequence analysis re-
vealed four mutations. All were functionally null, cre-
ating either a frameshift with a downstream stop codon
or an insert containing an internal stop codon. Of the
two mutations found in the siblings, one of them, in-
tervening sequence (IVS)-166ArG, generates a cryptic
donor splice site at position166 of an intron beginning
after Leu113, resulting in a 165-bp insertion of intronic
sequence at junction 339/340. The second is a 2-bp de-
letion, 2112delTC. Mutations in the third patient in-
clude a GrA substitution, well within the intron after
Lys203, which results in intronic inserts of 128 or 78
bp in the mRNA. The second mutation is a 1-bp inser-
tion, 3378insA. We conclude that the absence of MS
protein in these cblG variants is due to mutations caus-
ing premature translation termination and consequent
mRNA instability.
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Introduction
Methionine synthase (MS) is a cobalamin-dependent en-
zyme that catalyzes the methylation of homocysteine to
methionine, using 5-methyltetrahydrofolate as a methyl
donor (Fenton and Rosenberg 1995; Rosenblatt 1995).
The cobalamin cofactor acts as an intermediate methyl
carrier, such that the methyl group of 5-methyltetrahy-
drofolate is transferred first to the enzyme-bound
cob(I)alamin, to form methyl cobalamin, with subse-
quent transfer to homocysteine and regeneration of the
cob(I)alamin cofactor (Banerjee 1997). Over time, the
highly reactive cob(I)alamin cofactor may become oxi-
dized to cob(II)alamin, rendering the enzyme inactive.
Regeneration of the functional enzyme takes place
through the reductive methylation of the cob(II)alamin,
occurring through a distinct enzyme and using S-aden-
osyl methionine as the source of the methyl group (Lud-
wig and Matthews 1997). Recently, cDNAs coding for
MS (Gulati et al. 1996; Leclerc et al. 1996; Li et al.
1996; Chen et al. 1997) as well as for the MS reductase
responsible for its reactivation (Leclerc et al. 1998) were
cloned, making mutation detection and characterization
of patient cell lines possible.
Deficiency of MS activity has been shown to result in
the biochemical phenotypes of hyperhomocysteinemia,
homocystinuria, hypomethioninemia, and megaloblastic
anemia without methylmalonic aciduria (Watkins and
Rosenblatt 1989; Harding et al. 1997). Patients show a
range of clinical symptoms, including severe develop-
mental delay, ataxia, cerebral atrophy, neonatal seizures,
and blindness. Most cblG patients have reduced MS ac-
tivity, with normal accumulations of labeled [57Co]CN
cobalamin associated with the defective MS enzyme in
fibroblast-loading experiments (Sillaots et al. 1992).
However, three patient cell lines, two of which are from
siblings, show a reduced accumulation of labeled co-
balamin, none of which is bound to MS. The MS activity
of these cells is almost completely undetectable (Sillaots
et al. 1992; Gulati et al. 1997). Because these three cell
lines differ from the majority of cblG lines, they have
been classified as “cblG variants” (Sillaots et al. 1992).
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All three patients experienced severe developmental de-
lay, with neonatal seizures and elevated plasma homo-
cysteine.
In this study, we report four distinct mutations in the
cblG-variant patients. All four mutations would be ex-
pected to result in the premature truncation of a com-
plete MS protein. However, these mutations lead to
mRNA instability and insufficient mRNA to produce
any significant amount of MS enzyme. These results
show that the molecular defects in cblG variants are
consistently associated with a biochemically null phe-
notype.
Material and Methods
Cell Lines
Skin fibroblasts from the cblG-variant cell lines
WG1670, WG1671, and WG1655 were obtained from
the Montreal Children’s Hospital Cell Repository for
Mutant Human Cell Strains. DNA from the mother of
siblings WG1670 and WG1671 as well as from the sib-
lings themselves was kindly provided by J. P. Pfotenhauer
(Vanderbilt University School of Medicine, Nashville).
WG1671, the first child of unrelated parents, devel-
oped generalized seizures at 3 d of age. He became pro-
gressively hypotonic, and he suffered respiratory failure
at 10 wk of age. Elevated plasma and urine homocy-
steine (23 and 490 mmol/liter, respectively) but low
plasma methionine (5 mmol/liter) without macrocytic
anemia led to the initial diagnosis of methylenetetra-
hydrofolate reductase (MTHFR) deficiency. He was
treated with folinic acid, vitamin B12, vitamin B6, betaine,
and methionine and was well enough to be weaned from
the respirator by 14 wk of age. By 2 years of age, he
had severe psychomotor retardation and microcephaly.
A definitive diagnosis of MS deficiency was made by
means of complementation analysis of cultured fibro-
blasts, which placed him in the cblG complementation
group. He was subsequently treated with vitamin B12,
betaine, and aspirin, and, at age 8 years, methionine was
added. He has required femoral osteotomies and bilat-
eral adductor- and heel-cord release for neuromuscular
hip dislocations and contractures. At age 10 years, he
has short stature, microcephaly, rotatory nystagmus,
thin fingers, and spasticity. He smiles but is not able to
sit or speak.
WG1670, the younger sister of the patient described
above, was found to have elevated plasma homocysteine
(52 mmol/liter) and low methionine (8 mmol/liter) at 6 d
of age. She was presumed to have MTHFR deficiency
and was started on folinic acid, vitamin B12, vitamin B6,
betaine, and methionine, but these were discontinued by
her mother after a few days because the child appeared
to be doing well. At 3 mo of age, she had seizures and
respiratory distress, and medications were restarted. By
18 mo of age, she was microcephalic and severely de-
velopmentally delayed. At 2 years of age, the diagnosis
of cblG was established, and she was treated with vi-
tamin B12, betaine, and aspirin; at age 6 years, methio-
nine supplementation was added. At 9 years, she has
short stature, microcephaly, rotatory nystagmus, and pes
planus. She is able to walk, responds to simple com-
mands, and can speak a few words.
WG1655 presented with short stature, failure to
thrive, progressive weakness, hypotonia, ocular nystag-
mus, jaundice, feeding difficulties, and diarrhea at 7–10
wk of age (Wilden and Scott 1992). He had severe meg-
aloblastic anemia and neutropenia, homocysteinemia,
hypomethioninemia, and formiminoglutamic aciduria
without methylmalonic aciduria, which led to the di-
agnosis of a defect in methionine synthesis. Treatment
with hydroxycobalamin, methionine, and folinic acid re-
sulted in improved metabolite levels, improvement of
tone, and reduction of nystagmus, but poor growth, de-
velopmental delay, feeding difficulties requiring a gas-
trostomy, persistent anemia, and immunological deficits
at age 4 years (Wilden and Scott 1992).
All three of the patients—WG1670, WG1671, and
WG1655—were classified as cblG variants, in accor-
dance with findings from tests as described by Sillaots
et al. (1992). Test results showed reduced accumulations
of labeled cobalamin, virtually none of which associated
with the MS enzyme, and almost undetectable MS
activity.
Materials
Oligonucleotide primers were synthesized by R. Clar-
izio (Montreal Children’s Hospital Research Institute
Oligonucleotide Synthesis Facility, Sheldon Biotechnol-
ogy Center, McGill University, and ACGT Corporation,
Toronto). AMV reverse transcriptase (RT), Taq poly-
merase, Trizol, and DNAzol reagent were purchased
from Gibco BRL. Restriction enzymes were purchased
from New England Biolabs. The a-[35S] dATP (12.5 Ci/
mol) was purchased from Dupont, and the a-[32P] dATP
was from ICN Pharmaceuticals. The random-primed
DNA-labeling kit was from Boehringer. The Geneclean
III kit was purchased from Bio 101, the T/A cloning kit
from Invitrogen, and the Wizard Mini-preps from Pro-
mega. Sequenase kits were obtained from United States
Biochemicals.
Northern Blot Analysis
Total RNA from human fibroblast cell lines WG1670,
WG1671, and WG1655 and control 8074 was isolated
by use of the Trizol reagent. Cells were lysed in culture
dishes as recommended by the manufacturer. RNA con-
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Table 1
cDNA Sequence Segments Used in SSCP Analysis
PCR
Segment
Number
Nucleotide
Positiona
Annealing
Temperature
(C) Primer Pairsb
Uncut PCR
Product
(bp)c Enzyme
Digestion Products
(bp)d
1 56–635 66 3107/1209A 690 PstI 136, 286, 268
2 532–1657 62 309A/1827 1,125 AluI 261, 216, 363,
105, 180
3 1468–2057 60 1907A/1907B 590 HinfI 485, 105
4 1963–2698 60 1406E/1773 735 AvaII 165, 176, 394
5 2610–3856 60 1783/1107A 1,246 MseI 184, 196, 203,
414, 249
a Counted from the A of the ATG initiation codon.
b Sense/antisense oligonucleotides used to generate each segment.
c Expected size.
d Size of PCR fragments after digestion, listed in order from 5′ end of segment.
centrations were measured spectrophotometrically at
260 nm. A total of 15 mg of RNA from each patient
was denatured and subjected to electrophoresis in 1.5%
agarose formaldehyde gels and was then transferred to
Zetabind nylon membranes. The membranes were pre-
hybridized at 65C in 0.5 M phosphate buffer (pH 7.0),
1 mM EDTA, 7% SDS, 1% BSA, and 50 mg single-
stranded salmon-sperm DNA for 2 h. Hybridization was
performed overnight in fresh prehybridization buffer
with a 32P-labeled human MS cDNA probe. The cDNA
probes, generated through PCR with oligonucleotides
D1730 and D1733 (Leclerc et al. 1996), were labeled
with a-[32P] dATP by use of the random-primed DNA-
labeling kit. A phosphorimage analyzer (Fuji BAS 2000
Bio-Imaging Analyser; Fuji Medical Systems) was used
to detect radioactive signals.
Mutation Analysis
Total cellular RNA was isolated from fibroblast pellets
by use of the method of Chirgwin et al. (1979). Genomic
DNA was isolated with the use of DNAzol reagent ac-
cording to the manufacturer’s specifications. Reverse
transcription was performed with 25 mg total RNA in
reactions containing 2.5 U of AMV RT and 500 ng of
MS-specific terminal oligonucleotide primer (1107A in
the report by Leclerc et al. [1996]) in a total reaction
volume of 54 ml. Resultant cDNA was used as template
for PCR. PCR for five overlapping cDNA segments (ta-
ble 1) was performed in reactions containing 5 ml of
template; 1 ml each of dTTP, dGTP, and dCTP (10 mM);
0.5 ml of dATP (10 mM); and 1 ml of a-[35S] dATP (12.5
Ci/mol). SSCP analysis was performed as described else-
where (Leclerc et al. 1996). Fragments displaying shifts
were either subcloned and sequenced or sequenced di-
rectly. Sequencing was performed with use of the primers
of the initial PCR amplification, on both genomic DNA
and cDNA.
The confirmation of mutations in genomic DNA was
made by PCR-dependent diagnostic tests. Genomic PCR
was performed with 3 ml of template, 500 ng of specific
primers, 1 ml each of dNTPs (10 mM), and 3 U of Taq
polymerase in a 46-ml volume. Mutation 2112delTC was
identified through genomic sequencing and was con-
firmed by heteroduplex analysis by use of oligonucleo-
tides AA111 (5′-GTG ATA GGA AGC CAG ATT GAG)
and 511B (5′-GAA AAT TTC CCC ATA TTT TGC TAA
C) as primers for the PCR reaction. The product was
heated to 95C for 3 min, cooled to room temperature,
and run on 8% polyacrylamide gels. Mutation IVS-
166ArG was identified through genomic sequencing us-
ing primer pairs 1939 (5′-CTA CCT CAT GGT TTG
GGA GGA GAA) and 1938 (5′-GAT TCA TGA CCA
TCT AAT ACT CAG). The mutation was detected by
a test for the loss of an artificially created MseI restriction
site. Primer pairs used for this diagnostic test were
2802A (5′-CTT GTC TTT CCT TGC GCC TTT TA)
and 2808C (5′-AGA GCA CAT GTT CAT CCG TAG
GC), where the underlined T in 2802A replaced the C
in the normal sequence. To test for the mutation, 15 ml
of PCR product was digested in 2.2 ml of New England
Biolab’s Buffer 2, 2.2 ml of 10 # BSA, and 2.5 ml of
MseI. The GrA substitution found in the intron begin-
ning after Lys203 was identified through genomic se-
quencing by use of primer pairs 309A (5′-GAG CAG
GCC AAA GGA CTT CTG GAT) and 2802B (5′-CTG
CTC TTC AAC TGA GGA GTG GCT). The mutation
was confirmed by a test for the presence of an artificially
created BfaI site. The PCR primers used were AE358
(5′-TTT ACA GAT TCT ATT TTT TTG TTC T) and
AE359 (5′-TCT GAT TCC CAC AAC AAT GAA A),
where the underlined C in AE358 replaced the G in the
normal sequence. To test for the mutation, 15 ml of PCR
product was digested in 1.9 ml of NE Buffer 4 and 2 ml
of BfaI. Mutation 3378insA was first identified through
genomic sequencing with primer pairs 1774 (5′-TGC
CTC TCA GAC TTC ATC GCT CCC) and AE373 (5′-
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Figure 1 Results of northern analysis, showing levels of mRNA
in variant cell lines WG1670, WG1671, and WG1655. The control
pattern is on the right, with bands at 10 and 7.5 kb compared with
molecular-weight standards. At the bottom is the pattern obtained for
18S RNA as a control for differences in sample loading.
Figure 2 mRNA abnormalities in mutant fibroblast lines. A,
Agarose gel of RT-PCR products showing extra bands indicative of
splice defects in fibroblast lines WG1671 and WG1655. C1 is a control
cell line; B, the water blank. The bands on the left are molecular-
weight standards. B, Mechanism of splicing defects. In cell lines
WG1670 and WG1671, the ArG substitution at position 166 of
the intron after exon 3, beginning at Leu113, creates a 3′ acceptor site
165 bp upstream of the normal acceptor site. This new 3′ site replaces
the original downstream site, which has not been altered. In cell line
1655, the GrA substitution near the middle of the intron after exon
6, beginning at Lys203, creates a 3′ acceptor site and consequent gen-
eration of cryptic donor sites 78 and 128 bp farther downstream. All
inserts contain stop codons.
CTC CCT ACT GCC TGG CCT CTG TC). The diag-
nostic test for the 3378insA mutation was performed by
assaying for the loss of an artificially created AflII site.
The oligonucleotide primers used for PCR were AF345
(5′-GAC TAC AGC AGC ATC ATG CTT AA) and
AH450 (5′-GAC ACT GGT TCT AAG GGC TGA T),
where the underlined C and T in AF345 replaced the
normal nucleotides G and C, respectively. To test for the
mutation, 15 ml of PCR product was digested in 2 ml of
New England Biolab’s Buffer 2, 2 ml of 10# BSA, and
1 ml of AflII. All digestions were performed at 37C
overnight before the samples were subjected to electro-
phoresis on 8% polyacrylamide gels.
Results
Fibroblast cell lines WG1670, WG1671, and
WG1655 were analyzed by means of northern blot, with
a 1-kb PCR-generated fragment from the human MS
cDNA used as a probe. Normal cells showed bands at
7.5 and 10 kb, as expected (Chen et al. 1997). In con-
trast, none of the patient samples gave a detectable signal
under the same exposure conditions, although trace sig-
nals could be detected, after long exposure, by phos-
phorimage analysis (fig. 1). It was possible to amplify
these trace-level transcripts through RT-PCR, which al-
lowed an analysis of the resultant cDNA. The cDNA
was divided into five overlapping segments, as shown in
table 1. These fragments were amplified and evaluated
for possible mutations.
When RT-PCR products were run with use of agarose
gel electrophoresis, slower-running bands were found as-
sociated with fragment 1 of both WG1671 and WG1655
(fig. 2A). Subcloning and sequencing of the larger band
associated with WG1671 revealed a 165-bp insertion of
intronic DNA at junction 339/340 after exon 3 (num-
bered from the A of the initiation codon; fig. 2B). Se-
quencing of genomic DNA showed the insertion to be
the result of a substitution, IVS-166ArG, which gen-
erates a cryptic 3′ acceptor splice site at position 166
of the intron beginning after Leu113. The insertion con-
tains an in-frame stop codon 9 bp into the sequence, an
indication that translation is terminated. The mutation
was confirmed by diagnostic PCR with use of an arti-
ficially created MseI restriction site (fig. 3A). Alteration
of the sense oligonucleotide created an MseI cut site in
control DNA. The presence of the ArG mutation elim-
inated the restriction site. The mutation was confirmed
as heterozygous in genomic DNA from both siblings
(WG1670 and WG1671), since both cut and uncut
bands were present on the diagnostic gel. DNA from the
mother was also made available, and testing for the mu-
tation gave negative results.
The second mutation in WG1670 and WG1671 was
detected as a heteroduplex during SSCP analysis of frag-
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Figure 3 DNA-based diagnostic tests for the identified muta-
tions. DNA was amplified by PCR and either digested or not digested
with the designated restriction enzyme, and the fragments were re-
solved by PAGE. A, Test for IVS-166ArG. An artificially created MseI
site was introduced through alteration of the sense oligonucleotide
2802A, so that MseI digestion of control DNA cleaves the 214-bp
PCR product into fragments of 139, 53, and 23 bp (the last not shown).
The mutant sequence gives 139- and 76-bp fragments as cleavage
products. B, Test for 2112delTC. Electrophoresis of the PCR products
leaves trailing heteroduplexes in samples where the mutation is het-
erozygous. C, Test for GrA mutation in intron after Lys203. An ar-
tificially created BfaI site was introduced through alteration of the
sense oligonucleotide AE358, so that BfaI digestion results in cleavage
of the 150-bp PCR product to 126 and 24 bp (latter not shown) if
the mutation is present. D, Test for 3378insA. An artificially created
AflII was introduced through alteration of the sense oligonucleotide
AF345, so that digestion with AflII cleaves the 151-bp PCR product
to 132 and 19 bp (latter not shown) if the wild-type sequence is present.
For all panels, C, C1 and C2 are control DNA samples, and the num-
bered samples correspond to the WG designation of patient cell lines.
ment 4. It was sequenced directly from cDNA and ge-
nomic DNA PCR products and was shown to be due to
a 2-bp deletion, 2112delTC, resulting in a frameshift
and a downstream stop codon. A diagnostic test for the
mutation was made by heteroduplex analysis of PCR
products amplified from genomic DNA (fig. 3B). It was
confirmed in both siblings. DNA from the mother was
negative for the IVS-166ArG mutation and positive for
2112delTC, which confirmed that the mutations are on
separate chromosomes (fig. 3A and B).
Sequencing of the slower-running bands associated
with the RT-PCR of fragment 1 from cell line WG1655
yielded two insertions in the mRNA, one of 78 bp and
another of 128 bp, beginning after Lys203. The 78-bp
insertion was found to be a truncated version of the 128-
bp insertion, missing the last 50 bp. By means of genomic
sequencing, the insertions were discovered to be the re-
sult of a GrA substitution, near the center of the intron
after exon 6, that created a single cryptic 3′ acceptor
splice site (fig. 2B). For each insert, a cryptic 5′ donor
splice site was recruited to complete the new exon, one
at 78 bp and the other at 128 bp downstream of the
mutation. Neither of the newly created 5′ donor sites is
preferred, since the two transcripts appear to occur in
equal amounts. An in-frame stop codon occurs 9 bp into
the insertions. The mutation was confirmed by use of
diagnostic PCR on genomic DNA, with an artificially
created BfaI restriction site (fig. 3C). Alteration of the
sense oligonucleotide created a BfaI restriction site if the
GrA mutation was present. Because the mutation was
heterozygous, both cut and uncut bands were present
on the diagnostic gel.
In RT-PCR and SSCP analysis of segment 5, the second
mutation in WG1655 was detected as a band shift, rel-
ative to the controls. This segment was subcloned and
sequenced from both cDNA and genomic DNA. A 1-bp
insertion, 3378insA, was detected, which results in a
frameshift and a downstream stop codon. The mutation
was confirmed by diagnostic PCR on genomic DNA,
with use of an artificially created AflII restriction site.
Alteration of the sense oligonucleotide created an AflII
site that was eliminated if the inserted A was present
(fig. 3D). Because the mutation was heterozygous, both
cut and uncut bands were present in the diagnostic gel.
Screening for the four mutations in the other cblG cell
lines gave negative results, showing that the mutations
are unique to these individuals.
Discussion
All four mutations described here—the two splice mu-
tations and two frameshifts—are compatible with pre-
mature termination of translation and consequent insta-
bility of MS mRNA, as confirmed by the near-complete
absence of mRNA detected by northern blotting. These
molecular defects provide an explanation for the absence
of cobalamin-associated MS and for the profound de-
ficiency of enzyme activity in cultured fibroblasts that
defines the cblG-variant group (Sillaots et al. 1992). In
contrast, other cblG patients incorporate [57Co]CN co-
balamin into their MS protein, although they too have
deficient MS activity.
The three cblG-variant patients showed onset of dis-
ease in the first few days or weeks of life, with profound
neurological findings, hyperhomocysteinemia, and hy-
pomethioninemia. Poor growth, hypotonia, nystagmus,
and developmental delay were common features. One
of the three patients (WG1655) had severe megaloblastic
anemia. These findings are similar to those for patients
with severe cblG disease, as described by Watkins and
Rosenblatt (1989). Although the onset of disease may
also be early in non–cblG-variant patients, it may not
occur until either later in childhood or even adulthood
(Carmel et al. 1988). Patients with cblE disease, due to
a deficiency in MS reductase (Leclerc et al. 1998), also
show a broad spectrum of clinical findings that are sim-
ilar to those seen in the cblG patients.
It is significant that all four alleles in the two families
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we studied had null-type mutations. Thus, the relatively
rare cblG variants do not share a common genetic ab-
normality but instead share a biochemical characteristic,
the absence of MS protein. Although this leads to a
severe early-onset cblG phenotype, our findings confirm
that complete MS deficiency is not lethal.
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